• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

126.89 -0.89 (-0.70%)
Streaming Delayed Price Updated: 9:34 AM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results
October 23, 2024
From Sarepta Therapeutics, Inc.
Via Business Wire
Peeling Back The Layers: Exploring Sarepta Therapeutics Through Analyst Insights
October 21, 2024
Via Benzinga
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
October 21, 2024
Via Benzinga
Unveiling 15 Analyst Insights On Sarepta Therapeutics
October 21, 2024
Via Benzinga
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
October 18, 2024
Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments,... 
Via Benzinga
Analyst Scoreboard: 12 Ratings For Sarepta Therapeutics
October 04, 2024
Via Benzinga
Unveiling 26 Analyst Insights On Sarepta Therapeutics
September 06, 2024
Via Benzinga
How Is The Market Feeling About Sarepta Therapeutics?
August 16, 2024
Via Benzinga
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
October 18, 2024
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
Via Investor's Business Daily
2 High-Flying Growth Stocks With Massive Upside Potential
October 17, 2024
These innovative drugmakers have potential catalysts ahead. 
Via The Motley Fool
Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics
October 03, 2024
These two could become direct competitors relatively soon. 
Via The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2024
From Sarepta Therapeutics, Inc.
Via Business Wire
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
September 30, 2024
Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy 
Via MarketBeat
Exposures Product Safety
A Closer Look at 28 Analyst Recommendations For Sarepta Therapeutics
August 15, 2024
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today
August 12, 2024
Via Benzinga
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress
September 26, 2024
From Sarepta Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
September 18, 2024
Via Benzinga
Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors
September 16, 2024
From Sarepta Therapeutics, Inc.
Via Business Wire
These 2 Biotech Stocks Are Set to Soar
September 13, 2024
Innovative drugmakers developing treatments for conditions with high unmet needs can produce lucrative wins. 
Via The Motley Fool
Smart Money Is Betting Big In SRPT Options
August 08, 2024
Via Benzinga
Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year
September 05, 2024
From Sarepta Therapeutics, Inc.
Via Business Wire
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
September 03, 2024
Dyne Therapeutics revealed new clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, showing significant increases in dystrophin expression and meaningful... 
Via Benzinga
Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building
September 03, 2024
The company is hoping to rival Sarepa's Exondys 51. But three executives just departed on what is calls "unprecedented" test results. 
Via Investor's Business Daily
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 30, 2024
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 30, 2024
From Sarepta Therapeutics, Inc.
Via Business Wire
This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
August 19, 2024
Avidity Biosciences' stock has performed incredibly well in 2024. Its Duchenne muscular dystrophy drug is showing strong results in trials. 
Via MarketBeat
2 Biotech Stocks to Buy Hand Over Fist in August
August 12, 2024
Both of these biotechs are highly innovative companies. 
Via The Motley Fool
Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
August 11, 2024
These 10 stocks had the biggest drop last week, with McKesson Corporation, BIO-TECHNE Corp, and Warner Bros. Discovery, Inc. being the worst performers. 
Via Benzinga
How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics
August 09, 2024
The company is coming up fast with a platform that could take on several of Sarepta's approved treatments. 
Via Investor's Business Daily
McKesson Reports Weak Sales, Joins JFrog, Fastly, Warner Bros. Discovery And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
August 08, 2024
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap